Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients

Maria Gavriatopoulou, Despina Fotiou, Maria Roussou, Magdalini Migkou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Panagiotidis, Dimitra Gika, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, MD PhD, Eftathios Kastritis, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 3152.

https://doi.org/10.1182/blood.V130.Suppl_1.3152.3152

Published: 2017

Journal Articles

Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients

Efstathios Kastritis, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Magdalini Migkou, Dimitra Gika, Despina Fotiou, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Ntanasis-Stathopoulos, Despina Mparmparousi, Anastasia Gatou, Despina Katopi, Efstathios Manios, Michail Liontos, Stavroula Giannouli, Panagiotis Tsirigotis, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 3117.

https://doi.org/10.1182/blood.V130.Suppl_1.3117.3117

Published: 2017

Journal Articles

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Maria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Pieter Sonneveld, Meletios A. Dimopoulos

Blood (2017) 129 (4): 456–459.

https://doi.org/10.1182/blood-2016-09-742411

Published: 2017

Journal Articles

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

Maria Gavriatopoulou, Ramon Garcia-Sanz, Efstathios Kastritis, MD, Pierre Morel, Marie-Christine Kyrtsonis, MD PhD, Evridiki Michalis, Zafeirios Kartasis, Xavier Leleu, Giovanni Palladini, MD PhD, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, MD, Pieter Sonneveld, Meletios A Dimopoulos

Blood (2016) 128 (22): 2957.

https://doi.org/10.1182/blood.V128.22.2957.2957

Published: 2016

Journal Articles

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios Ziogas, Ioannis Panagiotidis, Despoina Fotiou, Dimitra Gika, Despoina Kalapanida, Eftychia Kafantari, Maria Roussou, Flora Zagouri, Stavroula Giannouli, Athanasios Zomas, Kostas Konstantopoulos, Meletios A. Dimopoulos

Blood (2015) 126 (23): 3045.

https://doi.org/10.1182/blood.V126.23.3045.3045

Published: 2015

Journal Articles

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Maria Roussou, Evdoxia Hadjiharissi, Argyris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2015) 126 (11): 1392–1394.

https://doi.org/10.1182/blood-2015-05-647420

Published: 2015

Includes: Supplemental data

Journal Articles

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Blood (2014) 124 (21): 2113.

https://doi.org/10.1182/blood.V124.21.2113.2113

Published: 2014

Journal Articles

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou, Despoina Kalapanida, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despoina Mparmparoussi, Athanasios Zomas, Dimitra Gika, Zafiris Kartasis, Charis Matsouka, Evangelos Kostis, Sofoklis Kontogiannis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4738.

https://doi.org/10.1182/blood.V124.21.4738.4738

Published: 2014

Journal Articles

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, Maria Roussou, Evangelos Terpos, Erasmia Psimenou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Despoina Mparmparoussi, Theodoros P. Vassilakopoulos, Dimitra Gika, Charis Matsouka, Ioannis Boletis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4769.

https://doi.org/10.1182/blood.V124.21.4769.4769

Published: 2014

Journal Articles

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Marios Bakogeorgos, Despoina Kalapanida, Spyros Orfanopoulos, Vasiliki Bampali, Thaleia Meletiou, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3464.

https://doi.org/10.1182/blood.V124.21.3464.3464

Published: 2014

Journal Articles

Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients

Meletios A. Dimopoulos, MD, Evangelos Terpos, Argiris S. Symeonidis, Eirini Katodritou, Anastasia Pouli, Sosana Delimpasi, Kostas Konstantopoulos, Michalis Michael, Eleftheria Hatzimichael, Maria Kotsopoulou, Dimitra Gika, Maria Roussou, Stavroula Giannouli, Costas Tsatalas, Efstathios Kastritis

Blood (2013) 122 (21): 1867.

https://doi.org/10.1182/blood.V122.21.1867.1867

Published: 2013

Journal Articles

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Efstathios Kastritis, Evangelos Terpos, Ioannis Melakopoulos, Pelagia Melea, Despoina Kalapanida, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Marina Iakovaki, Dimitrios Christoulas, Dimitra Gika, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3196.

https://doi.org/10.1182/blood.V122.21.3196.3196

Published: 2013

Journal Articles

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Magdalini Migkou, Nikolaos Kanellias, Dimitrios Christoulas, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3195.

https://doi.org/10.1182/blood.V122.21.3195.3195

Published: 2013

Journal Articles

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Blood (2013) 122 (19): 3276–3282.

https://doi.org/10.1182/blood-2013-05-503862

Published: 2013

Includes: Supplemental data

Journal Articles

Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients ≤65 Years of Age Compared to Patients >65 Years

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Dimitra Gika, Maria Gkotzamanidou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Meletios A Dimopoulos, MD

Blood (2012) 120 (21): 4030.

https://doi.org/10.1182/blood.V120.21.4030.4030

Published: 2012

Journal Articles

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Meletios A. Dimopoulos, MD, Maria Roussou, Efstathios Kastritis, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, MD, PhD, Panagiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas

Blood (2012) 120 (21): 438.

https://doi.org/10.1182/blood.V120.21.438.438

Published: 2012

Journal Articles

Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents

Meletios A Dimopoulos, MD, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, MD, PhD, Marie-Christine Kyrtsonis, Panagiotis Repousis, Zafiris Kartasis, Agapi Parcharidou, Michalis Michael, Eurydiki Michalis, Dimitra Gika, Argiris Symeonidis, MD, PhD, Konstantinos Zervas, Evangelos Terpos, Efstathios Kastritis

Blood (2012) 120 (21): 948.

https://doi.org/10.1182/blood.V120.21.948.948

Published: 2012

Journal Articles

Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,

Lia A Moulopoulos, Efstathios Kastritis, Evangelos Terpos, Maria Gkotzamanidou, Maria Roussou, Andreas Koureas, Magdalini Migkou, Maria Gavriatopoulou, Dimitra Gika, Vasilios Koutoulidis, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3920.

https://doi.org/10.1182/blood.V118.21.3920.3920

Published: 2011

Journal Articles

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,

Efstathios Kastritis, Lia A Moulopoulos, Maria Gkotzamanidou, Dimitra Gika, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3926.

https://doi.org/10.1182/blood.V118.21.3926.3926

Published: 2011

Journal Articles

Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma

Efstathios Kastritis, Evangelos Terpos, Maria Gkotzamanidou, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios Christoulas, Dimitra Gika, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 5081.

https://doi.org/10.1182/blood.V118.21.5081.5081

Published: 2011

NARROW

Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients

Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients ≤65 Years of Age Compared to Patients >65 Years

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents

Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,

Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only